Whether you're an investor, pharma partner, or research collaborator — the TBDS platform is open for conversation.
contact@interspacebio.comSeed and Series A capital with a life sciences or oncology focus. We are seeking investors who understand the urgency of multidrug resistance and recognize the value of a first-in-class physical lysis mechanism in a validated preclinical platform.
Seed · Series A Investment Inquiry →Licensing, co-development, or strategic partnership around specific TBDS constructs. With validated activity across breast, prostate, colorectal, lung, and head & neck cancers, individual construct rights or platform-level deals are available to discuss.
Licensing · Co-development Partnership Inquiry →Academic and institutional partners interested in TBDS biology, tumor microenvironment activation, protein engineering, or oncology translation. We welcome collaborations that deepen the science or accelerate IND-enabling studies.
Academic · Institutional Research Inquiry →We respond to all serious inquiries from investors, pharma partners, and research institutions. Reach us directly — no forms, no gatekeeping.
contact@interspacebio.comDisclosure: Interspace Biosystems is at the preclinical stage. All data referenced are from in vitro and xenograft studies. This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase securities.